

BeiGene Austria GmbH

Summarizing the approach and methods used in preparing the disclosure of transfers of value to health professionals and health organizations pursuant to Clause 9 of the PHARMIG Code of Conduct of 1 July 2007, lastly amended on 15 May 2020, the "Code"

Introduction

As a member company of the Association of the Austrian Pharmaceutical Industry (PHARMIG), and in accordance with the Code BeiGene Austria GmbH ("**BeiGene**") publishes the nature and extent of its monetary benefits provided to healthcare professionals (HCPs) and healthcare organizations (HCOs) in Austria.

This description of the procedure explains how these benefits are recorded and published.

Reporting Period

The current reporting period covers services provided between January 1st, 2022 and December 31st, 2022. Services paid after this date will be included in the 2023 report.

Consent for individual disclosure

With their contract from BeiGene HCPs received a privacy and consent statement informing them of BeiGene's disclosure of monetary benefits and requesting their consent to publish those benefits individually. BeiGene will publish those benefits to those HCPs who have given their express consent for individual publication. Payments to HCOs were disclosed in accordance with the declarations of consent of the institutions available via PHARMIG in accordance with Article 9 of the Code (as of 03/2023).

If an HCP wishes to withdraw the consent already given, this is possible at any time in writing to BeiGene at the address below:

BeiGene Austria GmbH, Teinfaltstraße 8/4; A-1010 Wien.

Methods of disclosure

When HCPs did not, or did not clearly, consent to individual disclosure, amounts were combined into a total amount and disclosed in aggregate.

Where possible, benefits are attributed to the appropriate HCP. If a benefit is paid to an HCP's employer, it is published within the corresponding HCO.

Within the aggregate publication, the number of HCPs and HCOs that received a benefit is listed for each benefit category. HCPs and HCOs that received one or more benefits are counted as one beneficiary per category.

Cross-border transactions on benefits from other BeiGene Group companies (worldwide) to HCPs and HCOs from Austria have been included in this publication.

Indirect benefits to HCPs and HCOs via a third party (e.g., contractor, agency, etc.) were published as a benefit to the HCPs and HCOs, when an HCP or HCO could be identified as beneficiary, and the HCP had given consent. When indirect support or sponsorship is provided by a third-party conference organizer, the benefits are published on behalf of the beneficiary HCO (organizer).

Assignment to the current reporting period

Event date is the date on which the event took place. Services in the following categories are included by event date in the reporting period of the reporting year: Service and consulting fees, conference or attendance fees, travel and lodging expenses, reimbursement of out-of-pocket expenses related to the service/consulting.

Payment date is the date payment was made to the respective recipient. Services in the following categories are included by payment date in the reporting period of the reporting year (January 01 to December 31, 2022): Donations (cash or in-kind) or other cash or in-kind contributions, sponsorships to medical institutions or third parties contracted by them to perform the event, service and consulting fees, grants for research and development

Multi-year agreements

In the case of multi-year agreements, only the benefits of the relevant reporting period are taken into account in the publication (January 1, 2022 to December 31, 2022).

Currency, exchange rate, rounding

All amounts are stated in Euros.

For benefits in a foreign currency, amounts are converted into the local currency based on a monthly average exchange rate. The average rate determined depends on the date of the benefit.

For each HCP or HCO, benefits in each category are rounded to the nearest cent. The published total for each HCP or HCO represents the sum of the amounts for each category.

Sales tax/VAT

The published benefits to HCPs or HCOs do not include sales or value-added tax, provided that the net amount could be determined. However, it is possible that indirect cash flows via third parties including taxes were reported to us.

Research and development

The published total includes services provided by BeiGene to HCPs and HCOs for non-clinical studies, Phase I -IV clinical trials and non-interventional studies.

For HCOs, payments to their respective contractors are also included.

Objections after publication

BeiGene carefully reviews and investigates all objections from HCPs/HCOs regarding transparency reports. Any changes resulting from these reviews will be published at regular intervals.

BeiGene Austria GmbH

30 June 2023